{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:30:05Z","timestamp":1761762605283,"version":"build-2065373602"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,3,25]],"date-time":"2004-03-25T00:00:00Z","timestamp":1080172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>To compare doxazosin and alfuzosin in patients with moderate to severe lower urinary tract symptoms (LUTS) suggestive of bladder outlet obstruction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>In all, 210 men with LUTS were randomized to receive doxazosin 1\u20138\u2003mg once daily or alfuzosin 5\u201310\u2003mg divided in two or three daily doses in a 14\u2010week, multicentre, double\u2010blind, baseline\u2010controlled, dose\u2010titration study. The International Prostate Symptom Score (IPSS) and maximum urinary flow rate were used to assess the efficacy of the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      At study completion, the mean dose of doxazosin was 6.1\u2003mg\/day and alfuzosin 8.8\u2003mg\/day. The least squares mean (\n                      <jats:sc>se<\/jats:sc>\n                      ) change from baseline in total IPSS was \u22129.23\u2003(0.6) for doxazosin and \u22127.45\u2003(0.6) (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001) for alfuzosin. The respective mean change from baseline in irritative symptoms was \u22123.5\u2003(0.2) and \u22122.8\u2003(0.3) (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001). The differences between the treatment groups were statistically significant in favour of doxazosin (total IPSS,\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.036; irritative symptoms,\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.049). The improvement between groups was also significantly different for postvoid residual urine volume, at \u221229.19 (8.6) and +\u200a9.59\u2003(8.9)\u2003mL for doxazosin and alfuzosin, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.002). Improvements in mean and maximum urinary flow rates were similar for both treatments, at +\u200a1.5 and +\u200a1.2, and +\u200a2.8 and +\u200a2.5\u2003mL\/s, respectively. Doxazosin and alfuzosin were both well tolerated, with most all\u2010cause adverse events reported as mild or moderate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The mean doses of doxazosin and alfuzosin used in this study were not equipotent. Doxazosin 6.1\u2003mg\/day produced significantly greater improvements than alfuzosin 8.8\u2003mg\/day in total and irritative urinary symptom scores and postvoid residual urine volume in men with moderate to severe LUTS. Changes in maximum and mean flow rates were comparable. Doxazosin and alfuzosin were both well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2003.04720.x","type":"journal-article","created":{"date-parts":[[2004,3,25]],"date-time":"2004-03-25T08:14:41Z","timestamp":1080202481000},"page":"757-762","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Comparative efficacy of two \u03b1\n                    <sub>1<\/sub>\n                    \u2010adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement"],"prefix":"10.1111","volume":"93","author":[{"given":"T.M.","family":"De Reijke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Klarskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,3,25]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.1.2.257"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199710050-00004"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)49698-4"},{"key":"e_1_2_8_5_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1742-1241.1997.tb11460.x","article-title":"Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double\u2010blind placebo\u2010controlled studies","volume":"51","author":"Mobley DF","year":"1997","journal-title":"Int J Clin Pract"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(94)80194-0"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66936-2"},{"key":"e_1_2_8_8_2","unstructured":"HansenBJ NordlingJ MensinkHJ WalterS MeyhoffHH.Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores urinary flow rates and residual: A multicentre double\u2010blind placebo\u2010controlled trial. ALFECH Study Group.Scand J Urol Nephrol Suppl1994157:169 \u2013 76"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93140-5"},{"key":"e_1_2_8_10_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000480880","article-title":"Effects of short\u2010term treatment with the alpha 1\u2010blocker alfuzosin on urodynamic pressure\/flow parameters in patients with benign prostatic hyperplasia","volume":"32","author":"Martorana G","year":"1997","journal-title":"Eur Urol"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00208-7"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1994.tb16546.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000480879","article-title":"Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double\u2010blind placebo\u2010controlled studies","volume":"32","author":"Abrams P","year":"1997","journal-title":"Eur Urol"},{"issue":"2","key":"e_1_2_8_14_2","first-page":"50","article-title":"Cultural and linguistic validation of questionnaires for use in international studies: the nine\u2010item BPH\u2010specific quality\u2010of\u2010life scale","volume":"32","author":"Boyle P","year":"1997","journal-title":"Eur Urol"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(93)90332-5"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35872-X"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1990.tb14657.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1992.tb15733.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1995.tb07709.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80409-9"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000052594"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00225-3"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67243-4"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65193-0"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80191-5"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80264-7"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2003.04720.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2003.04720.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:55:22Z","timestamp":1761749722000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2003.04720.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,25]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1111\/j.1464-410X.2003.04720.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2003.04720.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2004,3,25]]},"assertion":[{"value":"2004-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}